Organon & Co. — News

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-07-31 12:01:13

Organon (OGN) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1 per share a year ago.

zacks.com - 2026-07-31 10:46:12

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company's Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. About Organon Organon (NYSE: OGN) is a global h.

businesswire.com - 2026-07-31 08:30:00

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-07-28 10:01:21

VANCOUVER, BC / ACCESS Newswire / July 27, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties for the first half of 2026 and forecast for the remainder of the year. Highlights Approximately 44,000 metres of partner-funded drilling completed or underway on seven exploration stage projects where Orogen holds various royalty interests Over 7,000 metres of conversion drilling completed at Ermitano's Navidad/Winter deposit, where Orogen holds a cash-flowing 2% net smelter return ("NSR") royalty Received $1.72 million from the sale of projects and payments from exploration partners year to date Two new royalties created from project sales New pipeline of projects generated from partner-funded gold exploration in Nevada and Utah, and from Orogen's internally funded programs Additional six drill programs with 25,000 metres of drilling estimated in H2-2026 Paddy Nicol, CEO of Orogen, commented, "Orogen's strategy is built on a scalable business model of profitably generating highly prospective exploration stage mineral projects and advancing them through strategic partnerships, while retaining royalties.

accessnewswire.com - 2026-07-27 07:30:00

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups.

businesswire.com - 2026-07-24 08:00:00

Shareholders of Organon & Co. NYSE: OGN approved the company's proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting.

marketbeat.com - 2026-07-23 11:07:30

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will.

businesswire.com - 2026-07-16 07:30:00

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-07-15 10:01:16

VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Orogen Royalties Inc. (TSXV:OGN)(OTCQX:OGNNF) ("Orogen" or the "Company") is pleased to announce its shares have been qualified to begin trading on the OTCQX®Best Market ("OTCQX"). Orogen has upgraded to OTCQX from the OTCQB® Venture Market.

accessnewswire.com - 2026-07-10 08:00:00

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

zacks.com - 2026-07-03 10:01:17

Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026

gurufocus.com - 2026-06-25 14:00:00

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propo

gurufocus.com - 2026-06-24 15:00:00

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Organon will receive $14.00 in cash for each share of Organon that they own. KSF is seeking to determine whether this consideration and the process that led to it.

businesswire.com - 2026-06-24 14:28:00

KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA.

businesswire.com - 2026-06-23 05:30:00

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

zacks.com - 2026-06-22 10:02:17

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon completes agreement to license MIUDELLA®, Sebela's hormone-free IUD, expanding its long-acting reversible contraception portfolio.

businesswire.com - 2026-06-22 07:30:00

INCHEON, South Korea & KIRKLAND, Quebec--(BUSINESS WIRE)--Organon and Samsung Bioepis expand agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® (ustekinumab) in Canada.

businesswire.com - 2026-06-18 06:00:00

OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.

zacks.com - 2026-06-12 10:16:07

Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its arthritis drug, ​a biosimilar to Roche's Actemra, to treat ‌a life‑threatening immune reaction in some cancer patients and COVID-19 in patients needing breathing support.

reuters.com - 2026-06-10 08:44:42

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

zacks.com - 2026-06-09 10:01:14

Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.

fool.com - 2026-06-04 13:13:26

Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.

fool.com - 2026-06-04 11:16:36

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 2, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Organon & Co. ("Organon" or the "Company") (NYSE - OGN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Sun Pharmaceutical Industries Limited for $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75 billion. The investigation concerns whether the Organon Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

newsfilecorp.com - 2026-06-02 12:04:56

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

zacks.com - 2026-05-29 10:01:16

VANCOUVER, BC / ACCESS Newswire / May 26, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to report record revenue and after-tax profit for the three-month period ended March 31, 2026. Q1-2026 Highlights All figures are stated in Canadian dollars unless otherwise noted.

accessnewswire.com - 2026-05-26 07:30:00

Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon's Malaysia office to discuss the expansion of Hanmi's combination therapies into the Southeast Asian market. SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies' partnership in Southeast Asia.

globenewswire.com - 2026-05-21 05:06:00

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-05-18 10:00:30

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data acros

gurufocus.com - 2026-05-15 08:00:00

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to present 8 abstracts on affordability, access and adoption across women's health, biosimilar and general medicines portfolio at ISPOR 2026.

businesswire.com - 2026-05-15 07:30:00

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the appointment of Mr. Chad Wells to the Company's Board of Directors.

accessnewswire.com - 2026-05-06 08:00:00